Anti-secretory surgery and medicine was the mainstream in treating for ulcer disease until 1980's, when Barry Marshall and Robin Warren identified and named Helicobacter pylori (H. pylori). B. Marshall ingested and proved the infectivity of H. pylori in 1984. Marshall's illness and recovery, based on a culture of organisms extracted from a patient, fulfilled Koch's postulates for H. pylori and gastritis. Subsequent clinical trials proved that eradication of H. pylori may reduce the risk of recurrent peptic ulcer diseases that has dramatically changed the management of ulcer diseases. In addition to peptic ulcer disease, H. pylori has also been proved to be associated with variety of diseases, including gastric cancer, dyspepsia, and MALT (mucosa-associated lymphoid tissue) lymphoma. 3 It is well-established H. pylori eradication not only heals peptic ulcers but also prevents ulcer relapses and complications. 4 Animal studies, cohort studies and randomized trials have confirmed the causal association of H. pylori and gastric cancer (Table 1) . We also showed that mass screening and eradication of H. pylori eradication may reduce the incidence of gastric cancer in Matsu Island. 5 Eradication of H. pylori also leads to complete remission in 70% of patients with gastric MALT lymphoma 6 and decreases dyspeptic symptoms. 7 The discovery and treatment of H. pylori, an application of germ theory, is a triumph in modern medicine.
| MICROBIOME IN HUMAN HEALTH AND DISEASES
Germ theory lead a focus on single organisms and pathogenesis has led to tremendous advances in medicine. However, medical researchers found the incidence of many infectious diseases has decreased dramatically while that for autoimmune-related disorders has reciprocally increased. 8 The so-called hygiene is gained attention and suggested that childhood infections have a protective effect for allergy. The breakthrough of gene sequencing technologies frees scientists from the limitations of culturing bacteria and reveals more than 100 trillion symbiotic microorganisms within human beings playing an important role in human health and disease. Given that germ theory was established in the late 19th century, medical researchers have realized they should be adapted to incorporate the increased knowledge of host-microorganism interaction, and understand microbial communities are applicable to humans.
The gastrointestinal (GI) tract represents the largest microbial ecosystem and the gut microbiome is defined as the total genomic content of the complex microbial communities (the microbiota) and elements of the host such as the host epithelium, immune system, and products of both the microbes and host including metabolites. Considering as a forgotten organ, 9 the microbiota can carry out multiple metabolic functions ranging from catabolism, bioconversion and synthesis of a wide range of compounds that can have effects on both the microbiota and the host. 10 Emerging evidences have shown gut microbiota has a critical role in the steady-state of host immunity, 11 metabolism, 12 and even the gut-brain axis. 13 Figure 1 illustrates current concept of human microbiota and its related clinical problems.
Given the diverse functional repertoire of the gut microbiota, there is great interest in studying microbiota changes associated with diseased states. Alterations in the homeostasis of the microbiota or this microbiome are considered dysbiosis. Dysbiosis can represent a change in the numbers of microbes or a change in the diversity of the microbiota that may be related to certain diseases and health conditions. In this section, we highlight a few of the recent findings on the role of the microbiota in particular diseases or conditions, but we cannot touch on all of the emerging findings in a multitude of other diseases, including but not limited to autoimmune disease, 14 colorectal cancer, 15 liver disease, 16 and diabetes. 17 
| Clostridium difficile infection
Clostridium difficile infection (CDI) has been taught as an example of a disease where disruption of the normal microbiota plays a key role in the pathogenesis. Intestinal microflora defends itself from harmful microorganisms by a mechanism known as colonization resistance.
Gut microbiota plays in bile salt and bile acid metabolism, transforming bile salts into unconjugated primary and secondary bile acids.
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T A B L E 1 Helicobacter pylori and gastric cancer Primary bile acids, which the bacteria thrive upon, improving their colonization and triggering germination. 19 Antibiotic-mediated changes in the composition of the gut microbiota may lead to homeostatic imbalance through alterations in the gut barrier functions and result in mucosal immune defects, allowing C. difficile environmentally acquired spores to germinate and successfully colonize the gut. 20 This understanding of molecular mechanism has led to the exploration of novel treatments, such as microbiota replacement therapy. 21 
| Cardiovascular disease
Several types of microbes have been implicated as possible causative agents in acquired cardiovascular disease (CVD). 22 However, several randomized, placebo-controlled trials showed antibiotic treatment had no benefit in patients with coronary artery disease. 23 Recently, there is growing interest in a link between microbiota and CVD. Dietary choline is processed specifically by the gut microbiota to produce trimethylamine-N-oxide (TMAO). 24 Wang et al demonstrated levels of TMAO were associated with an increased risk of major cardiovascular events and death, 25 and poor prognosis 26 in patients with proven coronary heart disease. Apoe −/− mice treated with phosphatidylcholine metabolites resulted in increased aortic lesions, and modulation of gut microbiota inhibited choline-enhanced atherosclerosis. 24 Nine bacterial strains with TMA-producing properties in vitro led to accumulated plasma TMAO levels when transplanted into germ-free mice. 27 Thus, there is much interest in this microbiota-dependent pathway that may offer diagnostic and therapeutic potential for CVD.
| Irritable bowel disease
Irritable bowel syndrome (IBS) is a common GI disorder characterized by recurrent abdominal pain associated with alterations in bowel habits. 28 Multiple studies have demonstrated altered gut microbiota in patients with IBS and the alternations are thought to be associated with changes in GI function. 29 Studies demonstrated that patients with IBS had significantly less bacterial colonization of Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii, whereas increased bacterial colonization of Firmicutes, Lachnospiraceae, and Enterobacteriaceae, compared with healthy individuals. 30 The gut microbiota in patient with IBS may associate with increased intestinal permeability, 31 and increased expression of colonic toll-like receptors, 32 which in turn to induce alternations in GI motility. 33 One proposed pathway involved in IBS is through a microbiota-gut-brain axis, linking changes in the gut to symptom perception in the central nervous system. 34 Overall, these studies suggest that disruptions in gut microbiota may play a causative role in the pathogenesis of IBS.
| Inflammatory bowel disease
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory and destructive disease of the GI tract. The pathophysiological mechanisms are not fully understood but it is thought to be associated with inappropriate inflammation in the gut resulting from a combination of environmental and genetic risk factors. Multiple studies have documented the differences in the composition of the gut microbiota between patients with IBD and healthy individuals. 35 In short, gut microbiota in patients with IBD or experimental mice model has been associated with decreases of Bacteroides, and Firmicutes and increases in Proteobacteria, Campylobacter, Escherichia coli, Mycobacterium, Actinobaceria and Fusobacteria. 36,37 Dysbiotic changes were described in feces and mucosal biopsies from newly diagnosed, treatment-naive children with CD, suggesting that dysbiosis might precede clinical disease and develop independently of long-standing inflammation and/or medical therapy. 38 Thus, IBD is a microbiome related disease.
| Obesity and metabolic disease
The complex metabolic interplay between the commensal bacteria of the intestinal tract and the host has led to an examination of the potential role of the microbiome in metabolic conditions such as obesity and diabetes ( Figure 2 ). Studies have shown that there was an association between obesity and the intestinal microbiota in both humans and mouse models of disease. 39, 40 Ridaura et al demonstrated that the lean co-twin's microbiota can prevent adiposity gain in obese-recipient mice, if the mice are fed with an appropriate diet. 41 The precise mechanisms underlying this association are still under investigation. Bacterial metabolites and bacteria-derived components such as short chain fatty acids and bile acids can regulate human metabolism by influencing the expression of important metabolic regulatory peptides. 17 Host life style, exercise, diet, and hygiene F I G U R E 2 Gut microbiota and metabolic functions. The gut microbiota is involved in the metabolism of ingested nutrient in the bowel lumen. Several metabolites, including the short chain fatty acid, trimethylamine, primary and secondary bile acid, may be released into circulation and may have systemic effects several organs. These metabolites may affect the gluconeogenesis, insulin resistance, adiposity, and satiety and are associated with metabolic disorders. FMO, flavin-containing monooxygenase; FXR, farnesoid X receptor; GNB, gram-negative bacilli; LPS, lipopolysaccharides; PYY, peptide YY; SCFA, short chain fatty acid; TGR5, G-protein-coupled bile acid receptor; TMA, trimethylamine; TMAO, trimethylamine-N-oxide preferences, and medication change the composition of the gut microbiota. In turn, the dysbiosis of intestinal flora affects the production of immune mediators and induces both chronic inflammation and metabolic dysfunction. 42 
| GERM THERAPY
Emerging evidences show microbiome may play a role in a variety of diseases and it is rational to think that restoration of a beneficial microbial community or function would represent a novel treatment for certain diseases. The manipulation of the gut microbiota by diet, antibiotics, probiotics, prebiotics or synbiotics to promote, prevent, or reverse the development of specific diseases is evolving quickly in recent years (Table 2 ). Shows the rational of different bioactive component and the examples of their clinical applications.
| Antibiotic
Antibiotic therapy is undoubtful the most adequate treatment for traditional infectious diseases, such as pneumonia or cellulitis. For single pathogen and its related diseases, for example, H. pylori, revolution of eradication methods also reduced burden of these diseases significantly. 43 Moreover, antibiotics are useful in somewhat multipathogen related diseases. Hyperammonemia and hepatic encephalopathy are proposed to be related to urease-producing bacteria in human GI tracts. Rifaximin, a minimal absorbable oral antibiotic that acts locally in the GI tract, is a promising treatment of hepatic encephalopathy. 44 
| Dysbiosis and related treatment
Since dysbiosis is thought to be related to several disease entities, restoration of dysbiosis status to such "baseline" status is therefore proposed to be a therapy to aforementioned diseases. Nowadays, fecal microbiota transplantation (FMT) and probiotics are two common methods proposed to correct dysbiosis.
| Fecal microbiota transplantation
FMT is delivery of manipulated fecal material with its microbiota from a healthy human donor to a patient's GI tract. It was first utilized to treat recurrent CDI. 45 A growing number of studies used FMT to treat GI disorders over the past a few years, which included 
| Inflammatory bowel disease
Studies have showed dysbiosis in IBD and FMT has been the method to restore normal gut microbiota. Many clinical trials were done to evaluate the therapeutic effect of FMT on IBD, and the recent ones were listed in Table 3 . However, according to the published results, the efficacy of Clinical trials performed to evaluate the therapeutic effect of FMT on IBS were listed in Table 4 . However, according to current data of FMT and its effect to IBS, it is too limited to draw sufficient conclusions.
T A B L E 2 Manipulations of gut microbiota for treating diseases
Adequate-designed studies, such as standardized double blinded randomized clinical trials, need to be performed to evaluate the effect of FMT on IBS.
| Cirrhosis, hyperammonemia, and hepatic encephalopathy
Not only increasing of urease-producing bacteria, recent studies also disclosed gut microbiota dysbiosis status in patients with cirrhosis.
Cirrhosis dysbiosis ratio, the ratio of autochthonous/good bacteria (eg, Lachnospiraceae, Ruminococcaceae, and Clostridiales) to nonautochthonous/pathogenic bacteria (eg, Enterobacteriaceae and Streptococcaceae), is significantly higher in controls and patients with compensated cirrhosis than patients with decompensated cirrhosis. 85 This provided a hypothesis that FMT may be capable of treating hepatic encephalopathy. 86 Microbiome manipulation resulting in a favorable change to the gut microbiota may be a promising new area of therapy.
| Probiotics
Havenaar and Huisint Veld defined probiotic as a viable mono or mixed culture of bacteria which, when applied to animal or man, affects the host beneficially by improving the properties of the indigenous flora. 87 It is assumed that one could change his or her own gut flora by intake probiotics to increase the relative numbers of "beneficial bacteria", which might have certain impacts on immune function, digestion, metabolism, and brain-gut communication. 88 Many different bacterial species are chosen as probiotics, which include Lactobacillus spp., Propionibacterium spp., Peptostreptococcus spp., Bacillus spp., Lactococcus spp., Enterococcus spp., Pediococcus spp., Streptococcus spp., Bifidobacterium spp., Bacteroides spp., Akkermansia spp., and Saccharomyces spp. 89 Probiotics have shown positive responses to clinical treatment against several diseases and disorders, such as certain anti-pathogen activities, IBS, and allergic diseases. Moreover, the probable effect of probiotics in prevention and treatment of IBD, diabetes, obesity, cancer, and psychiatric diseases is under investigating, and some of them provide positive preliminary results.
| Adverse effects of germ therapy
FMT and probiotics are the most common germ therapy nowadays.
FMT has become standard treatment in treating recurrent CDI and using FMT to treat GI or non-GI disease becomes more and more popular. Probiotics are widely used and is one of the most commonly consumed dietary supplements in United States. 90 In this section, we will discuss adverse effect of germ therapy.
FMT is usually well tolerated, with an excellent short-term safety profile. Only few and mild, self-limiting adverse events, such as abdominal discomfort, fever, diarrhea and constipation, were reported. 49, 50 Mortality and pathogen transmission related to FMT has been reported. Death after FMT was caused by aspiration during sedation of colonoscopy. 91 One case of Cytomegalovirus infection, one case of norovirus infection and two cases of gram-negative bacteremia were reported after FMT. 92 Of note, disease flare-up has been reported after FMT in patients with IBD. 93 Because microbes may be linked to diseases inside or outside out gut, FMT has potential risk of transmitting harmful microbiota traits that cause diseases in the future. However, the majority of patients treated with FMT were followed up for less than 2 years in most of the published studies 94 and the study with the longest follow-up period only had 12 patients. 95 Most of the studies concentrated on GI symptoms only and these results cannot be directly extrapolated to long-term effects. An article in Open Forum Infectious Diseases reported that fecal transplants can result in the onset of obesity in the receiver. 96 In one instance, the donor (the patient's daughter) was a healthy but overweight woman. The recipient's suffered from no further CDI recurrence after the procedure but had become obese when she reported back to the hospital 16 months later. In summary, there is some evidence of the safety of the procedure itself, but the longterm safety to the patients' health has not been well described. Longterm follow-up is vital for understanding of the long-term implications of FMT treatment and the American Gastrointestinal Association has initiated FMT National Registry to assess short-and long-term patient outcomes associated with FMT.
In most countries, probiotics are categorized as health food, and are generally regarded as safe for most populations and little adverse effect is reported. However, there were still a number of case reports showing theoretical risks including systematic infections, deleterious metabolic activities, excessive immune status. 97 Probiotics and related supplement appeared to be well tolerated in most of the trials. A systemic review highlighted that harms reporting in published reports of randomized control trials assessing probiotics often is lacking or inadequate. Consequently, we cannot assume or conclude that probiotics are completely safe and secure. 98 A recent study showed probiotics delay the human fecal microbiome and the gut mucosal and luminal microbiome reconstitution to baseline following antibiotics treatment. They also delay the postantibiotic reconstitution of the human gut transcriptome. 99 The significance of such probiotics-induced delayed endogenous microbiome and host transcriptome reconstitution merit further studies. understanding, it is hoped that we will be in a position to develop new microbiome-based diagnosis and treatment strategies by tending to our microbial symbionts.
| CONCLUSION

